Literature DB >> 9446004

[Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection].

R Fünfstück1, E Straube, O Schildbach, U Tietz.   

Abstract

PROBLEM: A great variety of different antimicrobial chemotherapeutics is available for the treatment of urinary tract infections. Influencing the course of chronic diseases is a problem because recurrent diseases may result in disturbances of renal and bladder functions as well as in irreversible damages of the renal parenchyma. The present investigations are expected to clarify whether an effective prevention of reinfection in patients with chronically recurrent urinary tract infection is possible by a regular administration of L-methionine (Acimethin). PATIENTS AND METHODS: 33 female patients were included in the examinations. Following acute disease, 23 females (aged: 47.4 +/- 13.3 years) were treated with 3 x 1 tablet of Acimethin (L-methionine) daily over a period of 26 months. Ten female patients (aged: 47.4 +/- 12.2 years) taking 1 tablet of Nevigramon (nalidixic acid) three times daily over 21.6 months served as a control group. Before starting treatment and in the middle of the therapy period control examinations were performed and following the last drug administration so as to assess the therapeutic result.
RESULTS: No acute infection occurred during L-methionine treatment. All parameters of inflammation (leucocyte count, C-reactive protein, blood sedimentation rate, alpha 2-globulin concentration) were in the normal range; no impairment of renal function was observed. Although L-methionine, i.e. nalidixic acid, did not yield any significant changes in the range of bacteria, the adherence of uropathogenic microorganisms to the cells of the urinary tract was reduced. Before L-methionine treatment, the average load of the uroepithelial cells was 95.9 +/- 73.6 bacteria per cell. When the observation period was completed, 51.2 +/- 56.4 bacteria per cell were registered (p < 0.03). During nalidixic acid treatment, the rate of adherence was reduced from 74.0 +/- 88.4 to 34.4 +/- 37.8 bacteria per cell (p < 0.25). During L-methionine treatment, no Escherichia coli strains that are able to produce hemolysin or to form aerobactine were found. Among agents adhering to uroepithelial cells, however, an increase in their ability to produce mannose-resistant hemagglutination was conspicuous.
CONCLUSION: L-methionine is suitable to prevent reinfection with chronic urinary tract infection. The therapeutic result is essentially due to its influence on bacterial cytoadherence. In contrast to the established recommendations concerning the prevention of reinfection by the use of antibiotics and sulphonamides selecting resistant strains during long-term treatment, nothing is known about the development of resistance to L-methionine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9446004     DOI: 10.1007/bf03044782

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  25 in total

1.  Binding of Escherichia coli S fimbriae to cultured human endothelial cells.

Authors:  J Parkkinen; A Ristimäki; B Westerlund
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Prognosis in pyelonephritis: promise or progress?

Authors:  J W Smith
Journal:  Am J Med Sci       Date:  1989-01       Impact factor: 2.378

3.  Treatment of uncomplicated urinary tract infection in non-pregnant women.

Authors:  C E Mabeck
Journal:  Postgrad Med J       Date:  1972-02       Impact factor: 2.401

4.  Synthesis and secretion of hemolysin by Escherichia coli.

Authors:  W Springer; W Goebel
Journal:  J Bacteriol       Date:  1980-10       Impact factor: 3.490

5.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

6.  Effects of low concentrations of antibiotics on Escherichia coli adhesion.

Authors:  K Vosbeck; H Mett; U Huber; J Bohn; M Petignat
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

7.  [Comparative activity of norfloxacin and other chemotherapeutic agents on the adhesion of bacteria of the uro-vaginal tract to uroepithelial cells].

Authors:  N A Carlone; M Borsotto; A M Cuffini; D Savoia
Journal:  G Batteriol Virol Immunol       Date:  1985 Jul-Dec

8.  Effects of sublethal concentrations of antimicrobial agents on the hemagglutination, adhesion, and ultrastructure of pyelonephritogenic Escherichia coli strains.

Authors:  V Väisänen; K Lounatmaa; T K Korhonen
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

Review 9.  [Therapy of urinary tract infection].

Authors:  W Graninger; E Presterl; S Radosztics; F Thalhammer; W Emminger
Journal:  Wien Med Wochenschr       Date:  1991

10.  Relationship of type 1 pilus expression in Escherichia coli to ascending urinary tract infections in mice.

Authors:  A J Schaeffer; W R Schwan; S J Hultgren; J L Duncan
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

View more
  10 in total

1.  The effect of dietary factors on the risk of developing urinary tract infection.

Authors:  H Kalhoff
Journal:  Pediatr Nephrol       Date:  2004-08-20       Impact factor: 3.714

Review 2.  [Primary and secondary prevention of urinary tract infections].

Authors:  F M E Wagenlehner; W Vahlensieck; H W Bauer; W Weidner; K G Naber; H J Piechota
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

3.  [Prophylaxis of recurrent urinary tract infections].

Authors:  W Vahlensieck; H-W Bauer; H J Piechota; M Ludwig; F Wagenlehner
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

Review 4.  [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options].

Authors:  U Mehnert; M Nehiba
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 5.  [Neurogenic bladder function disorders in patients with meningomyelocele: S2k guidelines on diagnostics and therapy].

Authors:  R Stein; C Assion; R Beetz; M Bürst; R Cremer; A Ermert; M Goepel; E Kuwertz-Bröking; B Ludwikowski; T Michael; J Pannek; H Peters; D Rohrmann; I Rübben; A Schröder; R Trollmann; J W Thüroff; W Wagner
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

Review 6.  [Prevention and alternative methods for prophylaxis of recurrent urinary tract infections in women].

Authors:  W Vahlensieck; H Bauer
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

Review 7.  [Urological problems in patients with meningomyelocele. Diagnostic studies and management].

Authors:  R Stein; A Schröder; R Beetz; A Ermert; D Filipas; M Fisch; M Goepel; I Körner; B Schönberger; C Sparwasser; M Stöhrer; J W Thüroff
Journal:  Urologe A       Date:  2007-12       Impact factor: 0.639

8.  [Medical therapy of urinary tract infection].

Authors:  G Stein; R Fünfstück
Journal:  Internist (Berl)       Date:  2008-06       Impact factor: 0.743

9.  Lysine: Is it worth more?

Authors:  D Datta; A Bhinge; V Chandran
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

10.  Excess dietary methionine does not affect fracture healing in mice.

Authors:  Joerg H Holstein; Julia Schmalenbach; Markus Herrmann; Ilona Ölkü; Patric Garcia; Tina Histing; Wolfgang Herrmann; Michael D Menger; Tim Pohlemann; Lutz Claes
Journal:  Med Sci Monit       Date:  2012-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.